Development of an Epidermal Growth Factor Derivative with EGFR Blocking Activity

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Panosa, Clara ^a   Tebar, Francesc ^b   Ferrer Batallé, Montserrat ^a   Fonge, Humphrey ^c   Seno, Masaharu ^d   Reilly, Raymond M ^c,e   Massaguer, Anna ^a   de Llorens, Rafael ^a  

^a UNIVERSITY OF GIRONA   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c UNIVERSITY OF TORONTO   (Canada)

^d OKAYAMA UNIVERSITY   (Japan)

^e UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; RECOMBINANT EPIDERMAL GROWTH FACTOR; TRUNCATED EPIDERMAL GROWTH FACTOR; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER CELL; CELL GROWTH; CELL NUCLEUS; CELLULAR DISTRIBUTION; COMPETITIVE INHIBITION; CONTROLLED STUDY; DIMERIZATION; DRUG DESIGN; DRUG SPECIFICITY; HUMAN; HUMAN CELL; INTERNALIZATION; LIGAND BINDING; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; RECEPTOR BINDING;

BIOREACTORS; CELL LINE, TUMOR; CELL PROLIFERATION; EPIDERMAL GROWTH FACTOR; FERMENTATION; HUMANS; LIGANDS; MODELS, MOLECULAR; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN MULTIMERIZATION; PROTEIN TRANSPORT; PROTEOLYSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINANT PROTEINS;

EID: 84880846132     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0069325     Document Type: Article

References (45)

1. Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti AK, et al. (2012) Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets. 16: 15-31.
2. Sporn MB, Roberts AB, (1985) Autocrine growth factors and cancer. Nature 313: 745-747.
3. Ferrer-Soler L, Vazquez-Martin A, Brunet J, Menendez JA, De Llorens R, et al. (2007) An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa)-induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review). Int J Mol Med 20: 3-10.
4. Carrion-Salip D, Panosa C, Menendez JA, Puig T, Oliveras G, et al. (2012) Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands. Int J Oncol 41: 1128-1138.
5. Yotsumoto F, Sanui A, Fukami T, Shirota K, Horiuchi S, et al. (2009) Efficacy of ligand-based targeting for the EGF system in cancer. Anticancer Res 29: 4879-4885.
6. Revillion F, Lhotellier V, Hornez L, Bonneterre J, Peyrat JP, (2008) ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis. Ann Oncol. 19: 73-80.
7. Mas JM, Aloy P, Marti-Renom MA, Oliva B, Blanco-Aparicio C, et al. (1998) Protein similarities beyond disulphide bridge topology. J Mol Biol 284: 541-548.
8. Ogiso H, Ishitani R, Nureki O, Fukai S, Yamanaka M, et al. (2002) Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 110: 775-787.
9. Groenen LC, Nice EC, Burgess AW, (1994) Structure-function relationships for the EGF/TGF-alpha family of mitogens. Growth Factors 11: 235-257.
10. Nakamura T, Takasugi H, Aizawa T, Yoshida M, Mizuguchi M, et al. (2005) Peptide mimics of epidermal growth factor (EGF) with antagonistic activity. J Biotechnol 116: 211-219.
11. Blanco-Aparicio C, Molina MA, Fernandez-Salas E, Frazier ML, Mas JM, et al. (1998) Potato carboxypeptidase inhibitor, a T-knot protein, is an epidermal growth factor antagonist that inhibits tumor cell growth. J Biol Chem 273: 12370-12377.
12. Sitja-Arnau M, Molina MA, Blanco-Aparicio C, Ferrer-Soler L, Lorenzo J, et al. (2005) Mechanism of action of potato carboxypeptidase inhibitor (PCI) as an EGF blocker. Cancer Lett 226: 169-184.
13. Ferguson KM, Berger MB, Mendrola JM, Cho HS, Leahy DJ, et al. (2003) EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol Cell 11: 507-517.
14. Dawson JP, Berger MB, Lin CC, Schlessinger J, Lemmon MA, et al. (2005) Epidermal growth factor receptor dimerization and activation require ligand-induced conformational changes in the dimer interface. Mol Cell Biol 25: 7734-7742.
15. Ghrayeb J, Kimura H, Takahara M, Hsiung H, Masui Y, et al. (1984) Secretion cloning vectors in Escherichia coli. EMBO J 3: 2437-2442.
16. Ferrer Soler L, Cedano J, Querol E, de Llorens R, (2003) Cloning, expression and purification of human epidermal growth factor using different expression systems. J Chromatogr B Analyt Technol Biomed Life Sci 788: 113-123.
17. Chang JY, Lu BY, Li L, (2005) Conformational impurity of disulfide proteins: detection, quantification, and properties. Anal Biochem 342: 78-85.
18. Chang JY, Schindler P, Ramseier U, Lai PH, (1995) The disulfide folding pathway of human epidermal growth factor. J Biol Chem 270: 9207-9216.
19. Reilly RM, Gariepy J, (1998) Factors influencing the sensitivity of tumor imaging with a receptor-binding radiopharmaceutical. J Nucl Med 39: 1036-1043.
20. Motulsky HJ, Stannard P, Neubig R (1995) Prism; GraphPad Software Inc. 2.0.
21. Reilly RM, Kiarash R, Sandhu J, Lee YW, Cameron RG, et al. (2000) A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer. J Nucl Med 41: 903-911.
22. Canals F, (1992) Signal transmission by epidermal growth factor receptor: coincidence of activation and dimerization. Biochemistry 31: 4493-4501.
23. Sorensen HP, Mortensen KK, (2005) Advanced genetic strategies for recombinant protein expression in Escherichia coli. J Biotechnol 115: 113-128.
24. Marshall J, (2006) Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. Cancer 107: 1207-1218.
25. Benavente S, Huang S, Armstrong EA, Chi A, Hsu KT, et al. (2009) Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells. Clin Cancer Res 15: 1585-1592.
26. Matsunami RK, Yette ML, Stevens A, Niyogi SK, (1991) Mutational analysis of leucine 47 in human epidermal growth factor. J Cell Biochem 46: 242-249.
27. Ray P, Moy FJ, Montelione GT, Liu JF, Narang SA, et al. (1988) Structure-function studies of murine epidermal growth factor: expression and site-directed mutagenesis of epidermal growth factor gene. Biochemistry 27: 7289-7295.
28. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, et al. (2003) Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 284: 31-53.
29. Choi JH, Lee SY, (2004) Secretory and extracellular production of recombinant proteins using Escherichia coli. Appl Microbiol Biotechnol 64: 625-635.
30. Huang HW, Mohan SK, Yu C, (2010) The NMR solution structure of human epidermal growth factor (hEGF) at physiological pH and its interactions with suramin. Biochem Biophys Res Commun 402: 705-710.
31. Wilson KJ, Gilmore JL, Foley J, Lemmon MA, Riese DJ, (2009) Functional selectivity of EGF family peptide growth factors: implications for cancer. Pharmacol Ther 122: 1-8.
32. Foley J, Nickerson NK, Nam S, Allen KT, Gilmore JL, et al. (2010) EGFR signaling in breast cancer: bad to the bone. Semin Cell Dev Biol 21: 951-960.
33. Levkowitz G, Waterman H, Ettenberg SA, Katz M, Tsygankov AY, et al. (1999) Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol Cell 4: 1029-1040.
34. Countaway JL, Nairn AC, Davis RJ, (1992) Mechanism of desensitization of the epidermal growth factor receptor protein-tyrosine kinase. J Biol Chem 267: 1129-1140.
35. Theroux SJ, Latour DA, Stanley K, Raden DL, Davis RJ, (1992) Signal transduction by the epidermal growth factor receptor is attenuated by a COOH-terminal domain serine phosphorylation site. J Biol Chem 267: 16620-16626.
36. Brand TM, Iida M, Li C, Wheeler DL, (2011) The nuclear epidermal growth factor receptor signaling network and its role in cancer. Discov Med 12: 419-432.
37. Lin SY, Makino K, Xia W, Matin A, Wen Y, et al. (2001) Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol 3: 802-808.
38. Han W, Lo HW, (2012) Landscape of EGFR signaling network in human cancers: biology and therapeutic response in relation to receptor subcellular locations. Cancer Lett 318: 124-134.
39. Ebner R, Derynck R, (1991) Epidermal growth factor and transforming growth factor-alpha: differential intracellular routing and processing of ligand-receptor complexes. Cell Regul 2: 599-612.
40. Reddy CC, Wells A, Lauffenburger DA, (1998) Comparative mitogenic potencies of EGF and TGF alpha and their dependence on receptor-limitation versus ligand-limitation. Med Biol Eng Comput 36: 499-507.
41. Bishop WP, Lin J, Stein CA, Krieg AM, (1995) Interruption of a transforming growth factor alpha autocrine loop in Caco-2 cells by antisense oligodeoxynucleotides. Gastroenterology 109: 1882-1889.
42. Beaulieu JF, Quaroni A, (1991) Clonal analysis of sucrase-isomaltase expression in the human colon adenocarcinoma Caco-2 cells. Biochem J 280: 599-608.
43. Anzano MA, Rieman D, Prichett W, Bowen-Pope DF, Greig R, (1989) Growth factor production by human colon carcinoma cell lines. Cancer Res 49: 2898-2904.
44. Chen P, Cameron R, Wang J, Vallis KA, Reilly RM, (2003) Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts. J Nucl Med 44: 1469-1478.
45. Reilly RM, Kiarash R, Cameron RG, Porlier N, Sandhu J, et al. (2000) 111In-labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFR. J Nucl Med 41: 429-438.